000 02327nam a22004457a 4500
008 190314s20192019 xxu||||| |||| 00| 0 eng d
022 _a0889-8529
024 _a10.1016/j.ecl.2018.11.005 [doi]
024 _aS0889-8529(18)30592-9 [pii]
040 _aOvid MEDLINE(R)
099 _a30717901
245 _aConventional Radioiodine Therapy for Differentiated Thyroid Cancer. [Review]
251 _aEndocrinology & Metabolism Clinics of North America. 48(1):181-197, 2019 03.
252 _aEndocrinol Metab Clin North Am. 48(1):181-197, 2019 03.
253 _aEndocrinology and metabolism clinics of North America
260 _c2019
260 _fFY2019
265 _sppublish
266 _d2019-03-14
501 _aAvailable online from MWHC library: 1996 - present
520 _aCopyright (c) 2018 Elsevier Inc. All rights reserved.
520 _aThis article presents an overview of the use of radioactive iodine (131-I) in the treatment of patients with differentiated thyroid cancer. Topics reviewed include definitions; staging; the 2 principal methods for selection of 131-I dosage; the indications for ablation, adjuvant treatment, and treatment; the recommendations for the use of 131-I contained in the guidelines of the American Thyroid Association and the Society of Nuclear Medicine and Molecular Imaging; the dosage recommendations and selection of dosage approach for 131-I by these organizations; the use of recombinant human thyrotropin for radioiodine ablation, adjuvant therapy, or treatment; and the MedStar Washington Hospital Center approach.
546 _aEnglish
650 _a*Iodine Radioisotopes/tu [Therapeutic Use]
650 _a*Thyroid Neoplasms/rt [Radiotherapy]
650 _aHumans
650 _aIodine Radioisotopes/ad [Administration & Dosage]
651 _aMedStar Health Research Institute
651 _aMedStar Washington Hospital Center
656 _aMedicine/Endocrinology
656 _aMedicine/Nuclear Medicine
657 _aJournal Article
657 _aReview
700 _aVan Nostrand, Douglas
700 _aWartofsky, Leonard
700 _aYlli, Dorina
790 _aVan Nostrand D, Wartofsky L, Ylli D
856 _uhttps://dx.doi.org/10.1016/j.ecl.2018.11.005
_zhttps://dx.doi.org/10.1016/j.ecl.2018.11.005
942 _cART
_dArticle
999 _c4151
_d4151